BRIEF—Long Grove launches first generic in US market

Long Grove Pharmaceuticals has announced the launch of a new generic intended for multiple conditions including arthritis.

The Illinois-based company announced the launch of triamcinolone acetonide injectable suspension. The US Food and Drug Administration-approved generic is now available and is indicated for intramuscular and intra-articular use for multiple conditions including the treatment of various types of arthritis.

Triamcinolone acetonide injectable suspension is an AB-rated generic referencing Bristol Myers Squibb’s Kenalog-40. It is available in both single-dose and multiple-dose vial presentations and is the first in a series of planned launches in the coming year for the company.

The pharmaceutical company focuses on complex generics, including injectables and topical products, and is committed to improving customer choice while increasing access for patients.